Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Deals Medical Device PIC

TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices

Fineline Cube Aug 28, 2026
Company Drug PIC

Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen

Fineline Cube Aug 28, 2026
Company Drug PIC

Roivant’s Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis

Fineline Cube Aug 28, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Fineline Cube Aug 28, 2026
Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Fineline Cube Aug 28, 2026
Company Drug

Sino-Cuban JV Biotech Pharmaceutical Receives NMPA Approval for Nimotuzumab in Pancreatic Cancer

Fineline Cube Jun 25, 2023

Sino-Cuban joint venture (JV) Biotech Pharmaceutical Limited (BPL) announced last week that it has received...

Company Drug

Sarepta Therapeutics’ Elevidys Receives FDA Accelerated Approval for Duchenne Muscular Dystrophy

Fineline Cube Jun 25, 2023

US-based Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has announced that the U.S. Food and Drug Administration...

Company Drug

S-Evans Biosciences Receives NMPA Tacit Approval for Stem Cell Therapy in ARDS

Fineline Cube Jun 25, 2023

S-Evans Biosciences, a stem cell specialist based in Hangzhou, has obtained tacit clinical trial approval...

Company Deals

Kite Pharma’s Yescarta Marketing Rights Transferred to Gilead Sciences K.K. in Japan

Fineline Cube Jun 25, 2023

US immunotherapy specialist Kite Pharma, Inc. has announced that the Marketing Authorization for Yescarta (axicabtagene...

Company Drug

Hopstem Biotechnology’s hNPC01 Receives Tacit Approval for Stroke Sequelae Treatment from CDE

Fineline Cube Jun 25, 2023

Hopstem Biotechnology Co., Ltd, a neural stem cell specialist founded by neuroscientists and stem-cell biologists...

Company Deals

Edding Pharma Aims for Fifth IPO Attempt on Hong Kong Stock Exchange

Fineline Cube Jun 25, 2023

China-based Edding Pharma is gearing up for its fifth attempt to hold an initial public...

Drug Policy / Regulatory

CDE Releases Guidelines for Clinical Trials of Stem Cell Therapies and Derived Products

Fineline Cube Jun 25, 2023

The Center for Drug Evaluation (CDE) has released a set of “Guidelines for Clinical Trial...

Company Drug

Sciwind Biosciences Leads China’s Anti-Obesity Drug Market with GLP-1 Analog Ecnoglutide

Fineline Cube Jun 25, 2023

Sino-US biotech Sciwind Biosciences Co., Ltd has positioned itself as a frontrunner in China’s race...

Drug Policy / Regulatory

CDE Releases Draft Guidelines for Antibody Drug Conjugate Research and Evaluation

Fineline Cube Jun 25, 2023

The Center for Drug Evaluation (CDE) has released a draft set of “Guiding Principles for...

Company Deals

Aureka Biotechnologies Secures $10 Million in Seed Funding for AI-Driven Biotechnology

Fineline Cube Jun 25, 2023

Aureka Biotechnologies Inc., a California-based artificial intelligence (AI)-empowered biotech company, has successfully raised USD 10...

Company Drug

Jiangsu Hengrui’s Camrelizumab Earns Full Approval for Advanced Hepatocellular Carcinoma in China

Fineline Cube Jun 21, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the transition of its programmed death-1 (PD-1)...

Company Drug

Biocytogen Pharmaceuticals Receives CNIPA Patent for RenMab Human Antibody Mice Platform

Fineline Cube Jun 21, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced receiving a prestigious patent award...

Company Drug

BeiGene Initiates First-in-Human Trial for Next-Generation BCL-2 Inhibitor BGB-21447

Fineline Cube Jun 21, 2023

China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the first patient dosing in...

Company Drug

Jiangsu Hengrui Pharmaceutials’ SHR-1209 for Hypercholesterolemia Accepted for NMPA Review

Fineline Cube Jun 21, 2023

China-based Jiangsu Hengrui Pharmaceutials (SHA: 600276) has announced that a market filing for its Category...

Company Drug

Minghui Pharmaceutical Achieves First Dosing Milestone in Phase I Studies for ADC Candidates

Fineline Cube Jun 21, 2023

China-based biotech Minghui Pharmaceutical Inc. has reported that the first dosing has been completed in...

Company Deals

Xiamen ITG Group and Fosun Health Collaborate on Big Health Industry Fund and Medical Device Commercialization

Fineline Cube Jun 21, 2023

China-based Xiamen ITG Group Co., Ltd. (SHA: 600755) and Shanghai Fosun Health Technology (Group) Co.,...

Company Medical Device

Australian Scleral Lens Epicon A Approved by China’s NMPA as 10th Novel Product

Fineline Cube Jun 21, 2023

Ruitai Bio’s Epicon A, a scleral lens product from Australia, has been approved by the...

Company Drug

CDE Considers Breakthrough Therapy Designation for Beijing Mabworks’ MIL162 and Amgen’s AMG 890

Fineline Cube Jun 21, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Beijing Mabworks Biotech Co., Ltd’s...

Company Drug

Fujian Cosunter Pharmaceutical’s COVID-19 Drug GST-HG171 Meets Primary Endpoint in Phase II/III Study

Fineline Cube Jun 21, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that the pivotal Phase II/III...

Company Drug

Boehringer Ingelheim’s Spevigo on Track for Priority Review for GPP Flare Prevention in China

Fineline Cube Jun 21, 2023

Germany-based Boehringer Ingelheim’s (BI) interleukin-36 receptor (IL-36R)-targeted orphan drug, Spevigo (spesolimab), in subcutaneous injection form,...

Posts pagination

1 … 559 560 561 … 713

Recent updates

  • Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma
  • Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential
  • HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
  • AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
  • Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Company Drug

HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.